1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6C1A174BA130F337665257EF30041C0BE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-enabling-marketing-insights-superior-competitiveness-faster-market-research-approvals-managing-honoraria-non-conforming-requests?opendocument
18
19opendocument
2034.226.234.20
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Market Research, Analytics and Forecasting Process Excellence and Productivity Management

Enabling Marketing Insights and Superior Competitiveness Through Faster Market Research Approvals: Managing Honoraria & Non-Conforming Requests

ID: 5385


Features:

17 Info Graphics

14 Data Graphics

140 Metrics

10 Narratives


Pages/Slides: 43


Published: 2015


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Enabling Marketing Insights and Superior Competitiveness Through Faster Market Research Approvals: Managing Honoraria & Non-Conforming Requests"

STUDY OVERVIEW

Market research studies provide biopharmaceutical companies with strategic insights required to compete successfully in a fast-changing market. However, delays in the launch of critical market research projects can slow down the decision-making process, resulting in missed opportunities and increased costs.


Likewise, with the introduction of the Sunshine Act it is important for biopharmaceutical companies to establish a standard review process for honoraria rates to accelerate the market research approval process.


Research and consulting leader, Best Practices, LLC undertook this benchmarking study to investigate how leading companies manage honoraria services and non-conforming requests to enable fast and effective market research approvals. Market research leaders can use the insights from this study as a guide for the principal factors affecting honorarium.



KEY TOPICS

  • Best Practices of High-Performing Companies
  • Managing Honoraria Services
  • Managing Non-conforming Requests
  • Field Interviews & Executive Verbatims
  • Path Forward Recommendations


KEY METRICS
  • Do you Differentiate Honoraria Rates for These Respondent Types to Incent them to Participate in Market Research
  • Rate the Effectiveness of Various Criteria to Set the Honoraria
  • Factors That Dictate Honoraria Rate Differences
  • Use of Honoraria Rate Tools to Help Support Fast and Effective Market Research Approvals
  • Do you Vary Honoraria Rates - If Yes, Explain
  • Percentage of Market Research Requests with Exceptions
  • Management Approaches Used to Reduce Exception Reviews

SAMPLE KEY FINDINGS

Fair Market Value (FMV) Honoraria Process: Employ a multi-step process to validate FMV honoraria rates (Labor rates + MR Rate Cards + Real World Recruitment). Best-in-class companies have standardized approaches to setting honoraria rates, the frequency of update and multiple sources to validate what is “fair market value.” Additionally, high performers have standardized the process by which to re-evaluate honoraria rates in market niches where existing rates and FMV seem to be disconnected.

METHODOLOGY

Best practices, LLC engaged 22 executives from 21 leading pharmaceutical, biotech, and life sciences companies. Eleven companies responded on behalf of rare disease markets. Eight companies participated in deep-dive interviews about the drivers of operational excellence.


Industries Profiled:
Pharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care; Technology; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbvie; actavis; Amgen; AstraZeneca; Bayer; Biogen; Boehringer Ingelheim; CSL Behring; Fresenius Kabi; Genentech; Grifols; Jazz Pharmaceuticals; Lilly; NeedleTech Products Inc.; Novartis; Novo Nordisk; Philips Healthcare; Roche; Sanofi; Teva Pharmaceutical Industries Ltd; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.